KRAS and neoplasm: Each patient was classified as KRAS positive (i.e. KRAS mutations in tumor and plasma samples), KRAS negative (i.e. KRAS wild-type in tumor and plasma samples), or with discordant KRAS status in tumor and plasma samples.